PepGen Inc.

NasdaqGS PEPG

PepGen Inc. Price to Book Ratio (P/B) on January 14, 2025

PepGen Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

PepGen Inc. 52-week high Price to Book Ratio (P/B) is 4.26 on July 26, 2024, which is NA below the current Price to Book Ratio (P/B).
PepGen Inc. 52-week low Price to Book Ratio (P/B) is 1.78 on August 13, 2024, which is NA below the current Price to Book Ratio (P/B).
PepGen Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 3.02.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: PEPG

PepGen Inc.

CEO	Dr. James G. McArthur Ph.D.
IPO Date	May 6, 2022
Location	United States
Headquarters	245 Main Street
Employees	76
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years